Medical Disclaimer: ShedPilot is a nutrition and wellness app, not a medical provider. This content is for educational purposes only. Always consult your healthcare provider before starting any medication or supplement.
Beyond Weight Loss
When the SELECT trial published its results in 2023, it changed the conversation about GLP-1 medications permanently. The trial enrolled over 17,500 adults with obesity and established cardiovascular disease — but without diabetes — and found that semaglutide reduced the risk of major adverse cardiovascular events including heart attack, stroke, and cardiovascular death by 20% compared to placebo.
The significance of this finding extended in two important directions. First, the benefit was seen in people without diabetes. Second, the cardiovascular protection appeared to go beyond what weight loss alone would predict — suggesting GLP-1 has direct effects on the heart and blood vessels independent of how much weight a person loses.
20%
Reduction in major cardiovascular events in the SELECT trial
17,500+
Participants enrolled in the SELECT outcomes trial
3+ yrs
Average follow-up duration in the SELECT trial
How GLP-1 Protects the Heart
Direct Receptor Effects
GLP-1 receptors are present in the heart muscle and coronary blood vessels. Activation of these receptors has been shown in laboratory studies to reduce inflammation in arterial walls, improve heart muscle function after injury, and reduce the extent of damage caused by reduced blood flow. These direct effects are believed to contribute meaningfully to the cardiovascular benefits observed in humans.
Metabolic Improvements
GLP-1 medications improve multiple metabolic cardiovascular risk factors simultaneously — blood pressure, blood sugar, triglycerides, and body weight. Each improvement independently reduces cardiovascular risk, and their combined effect is greater than any single change alone.
Inflammation Reduction
Chronic low-grade inflammation is a major driver of atherosclerosis and cardiovascular disease. GLP-1 medications have demonstrated measurable anti-inflammatory effects in multiple studies, which may partly explain why their heart benefits exceed what weight loss alone would predict.
What This Means for GLP-1 Users
If you are on a GLP-1 medication primarily for weight loss, you are likely also receiving meaningful cardiovascular protection — particularly if you have existing risk factors like high blood pressure, elevated cholesterol, or a family history of heart disease.
In March 2024, the FDA approved semaglutide (Wegovy) specifically for reducing cardiovascular risk in adults with obesity — making it the first obesity medication ever approved for a cardiovascular indication.
New BMJ Study — Published August 5, 2026: A large real-world analysis published in The BMJ examined nearly 53,000 adults with type 2 diabetes, established heart disease, and obesity or overweight. Patients taking tirzepatide (Zepbound/Mounjaro) had a 32% lower risk of the composite outcome of heart attack, stroke, or death from any cause compared to patients taking sitagliptin (a DPP-4 inhibitor). After one year, event rates were approximately 2.9% in the tirzepatide group versus 4.4% in the sitagliptin group — equating to roughly one cardiovascular event prevented for every 70 patients treated. The study also found tirzepatide was associated with a 36% lower risk of hospitalization for serious infection and up to 60% lower infection-related mortality, findings that were unexpected in magnitude. These are observational data from insurance claims (not a randomized controlled trial), but the results reinforce the emerging picture that GLP-1-based therapies — particularly the dual GIP/GLP-1 approach of tirzepatide — may deliver broad systemic benefits beyond weight loss itself. Source: The BMJ, August 5, 2026 (Technical University of Munich).
FDA Approval — August 28, 2026: The FDA approved Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes at high risk for cardiovascular events. This makes tirzepatide the second GLP-1-class drug to receive a cardiovascular risk reduction approval after Wegovy's 2024 approval in obesity. The approval was grounded in SURPASS-CVOT — the largest and longest tirzepatide study ever conducted (13,000+ participants, 30 countries, 4.5+ years) and the first cardiovascular outcomes trial to compare two incretin medicines head-to-head. Mounjaro was non-inferior to Trulicity (dulaglutide), achieving a 0.92 hazard ratio for MACE (95.3% CI: 0.83–1.01) — an 8% lower event rate. For patients with type 2 diabetes and established or high cardiovascular risk, Mounjaro now joins Ozempic and Victoza as FDA-approved options with proven heart benefit. Source: Eli Lilly / FDA, August 28, 2026.
Washington University / BMJ Medicine — September 20, 2026: A study of 333,000+ U.S. veterans with type 2 diabetes found that stopping GLP-1 therapy for even six months was associated with a significant increase in cardiovascular risk. After two years off therapy, the risk of heart attack, stroke, or death was up to 22% higher than in patients who continued treatment — effectively erasing the cardiovascular benefits accumulated during use. Restarting treatment restored only partial protection, suggesting that treatment gaps leave a lasting mark on cardiovascular health. For high-risk patients, the findings argue for viewing GLP-1 therapy as ongoing rather than episodic. Source: Washington University in St. Louis / BMJ Medicine, September 20, 2026.